NCT02338245 is a Phase 2 clinical trial of ASLAN001 in Metastatic Breast Cancer, sponsored by ASLAN Pharmaceuticals.

Who is sponsoring NCT02338245?

NCT02338245 is sponsored by ASLAN Pharmaceuticals.

What drugs are being tested in NCT02338245?

Interventions in NCT02338245: ASLAN001, Lapatinib, Capecitabine.

What condition does NCT02338245 study?

NCT02338245 studies Metastatic Breast Cancer.

Is NCT02338245 still recruiting?

NCT02338245 is currently completed. Last updated 17 October 2017.

Last reviewed 2017-10-17 · How we verify

NCT02338245

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab

Completed Phase 2 Last updated 17 October 2017

What this trial tests

Phase 2 trial testing ASLAN001 in Metastatic Breast Cancer in 200 participants. Completed in 25 August 2016.

Timeline

29 December 2014

Primary endpoint
19 May 2016

25 August 2016

Quick facts

Lead sponsor	ASLAN Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	29 December 2014
Primary completion	19 May 2016
Estimated completion	25 August 2016
Sites	19 locations across Hong Kong, New Zealand, Taiwan, South Korea, Philippines, Australia, Singapore

Drugs / interventions tested

ASLAN001 — full drug profile →
Lapatinib (LAPATINIB) — full drug profile →
Capecitabine (capecitabine) — full drug profile →

Conditions studied

Metastatic Breast Cancer — all drugs for Metastatic Breast Cancer →

Sponsor

ASLAN Pharmaceuticals — full company profile →

Who can join

18 and older, female only, with Metastatic Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, randomized, parallel group Phase 2A/2B study to evaluate the clinical activity of ASLAN001 in combination with capecitabine compared with lapatinib in combination with capecitabine in patients with HER2 positive metastatic breast cancer that has failed on prior trastuzumab therapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells.
Liu CY, Chu PY, Huang CT, Chen JL, et al · · 2019 · cited 25× · PMID 30658422 · DOI 10.3390/cancers11010105
Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
James N, Owusu E, Rivera G, Bandyopadhyay D. · · 2024 · cited 9× · PMID 38892472 · DOI 10.3390/ijms25116285
Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?
Beaumont H, Faye N, Iannessi A, Chamorey E, et al · · 2023 · cited 4× · PMID 36098367 · DOI 10.1002/cam4.5236
Differences in Sensitivity to New Therapies Between Primary and Metastatic Breast Cancer: A Need to Stratify the Tumor Response?
Beaumont H, Faye N, Iannessi A, Chamorey E, et al · · 2020 · cited 1× · DOI 10.21203/rs.3.rs-92580/v1

Verify or expand the search:

Other trials of ASLAN001

Trials testing the same drug.

NCT03499626 — Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) · Phase 1, PHASE2 · unknown
NCT07166367 — Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer · Phase 2 · terminated
NCT02648425 — Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine · Phase 1 · completed

Other recruiting trials for Metastatic Breast Cancer

Currently open trials in the same condition.

NCT07524855 — A Study of HLD-0117 in Patients With Metastatic Breast Cancer · Phase 1 · recruiting
NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT07347600 — A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, · recruiting

Other ASLAN Pharmaceuticals trials

Trials by the same sponsor.

NCT05865041 — Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants · Phase 2 · unknown
NCT05694884 — Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab · Phase 2 · unknown
NCT05158023 — Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis · Phase 2 · completed
NCT04090229 — A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, · Phase 1 · completed
NCT03721263 — Study of ASLAN004 in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02338245 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ASLAN Pharmaceuticals
Last refreshed: 17 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02338245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing